doctoralThesis
Estudo imuno-histoquímico e in vitro de proteínas do sistema ativador de plasminogênio em carcinomas de células escamosas de língua oral
Fecha
2020-02-14Registro en:
MAFRA, Rodrigo Porpino. Estudo imuno-histoquímico e in vitro de proteínas do sistema ativador de plasminogênio em carcinomas de células escamosas de língua oral. 2020. 143f. Tese (Doutorado em Patologia Oral) - Centro de Ciências da Saúde, Universidade Federal do Rio Grande do Norte, Natal, 2020.
Autor
Mafra, Rodrigo Porpino
Resumen
Squamous cell carcinoma (SCC) is the most frequent malignant neoplasm of the oral cavity and
has an unfavorable prognosis. Thus, studies have sought to clarify the role of biomarkers in the
biological behavior of oral SCC. Within this context, urokinase-type plasminogen activator
(uPA) and its receptor (uPAR), as well as plasminogen activator inhibitor 1 (PAI-1), are
particularly interesting. The present study analyzed, by means of immunohistochemistry, the
expressions of uPA, uPAR and PAI-1 in oral tongue SCC (OTSCC) and their relationship with
clinicopathological parameters. This experiment also evaluated the in vitro effects of
recombinant human PAI-1 (rhPAI-1) on the OTSCC-derived cell line SCC-25. The
immunoexpression of uPA, uPAR and PAI-1 was analyzed semiquantitatively in neoplastic
cells of the invasion front of 60 OTSCC cases. Aiming to determine the association between
immunohistochemical findings, clinicopathological variables and survival rates, the cases were
classified as low expression (≤50% of positive cells) and high expression (>50% of positive
cells). The following groups were analyzed in the in vitro experiment: G0 (control; cells
cultured in the absence of rhPAI-1), G10 (cells treated with 10 nM rhPAI-1), and G20 (cells
treated with 20 nM rhPAI-1). Differences between these groups were investigated using the
following assays: cell viability (Alamar Blue), cell cycle (staining with propidium iodide, PI),
apoptosis/necrosis (staining with Annexin V and PI), migratory activity (Wound healing), and
cell invasion (Transwell). Immunohistochemical analysis revealed high expression of uPA in
most OTSCC cases, but there were no significant associations with clinicopathological
parameters. The high membrane expression of uPAR and PAI-1 was associated with local
recurrence (p=0.019) and high tumor budding (p=0.046), respectively. Membrane expression
of PAI-1 also presented a significant association with high-risk cases (p=0,043). Statistical
analysis demonstrated no significant associations between the immunohistochemical variables
(uPA, uPAR and PAI-1) and prognostic indicators of OTSCC (disease-specific and disease-free
survival). In the in vitro experiment, 24 hours after administration of rhPAI-1, G10 and G20
exhibited greater cell viability compared to the control group (p=0.02), as well as increased
progression to the S phase of the cell cycle (p=0.024). There were no significant differences in
the percentages of apoptotic or necrotic cells between groups. In the groups cultured in the
presence of rhPAI-1, migratory activity (p=0.039) and invasion potential (p=0.039) were found
to be increased after 24 and 72 hours, respectively. The findings of this study suggest the
involvement of uPA, uPAR and PAI-1 in the pathogenesis of OTSCC. Nevertheless, the
expression of these biomarkers may not be related to survival of patients. The in vitro results
suggest that PAI-1 exerts stimulatory effects on cell proliferation, migration and invasion and
may therefore contribute to the biological aggressiveness of OTSCC.